Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron Read more about Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
BioNTech Receives Priority Medicines (PRIME) Designation from EMA for Enhanced Regulatory Support of CAR-T Candidate BNT211 in Testicular Cancer Read more about BioNTech Receives Priority Medicines (PRIME) Designation from EMA for Enhanced Regulatory Support of CAR-T Candidate BNT211 in Testicular Cancer
BioNTech Starts Construction of First mRNA Vaccine Manufacturing Facility in Africa Read more about BioNTech Starts Construction of First mRNA Vaccine Manufacturing Facility in Africa
BioNTech to Host First Edition of Innovation Series on Diversified Pipeline, Latest Technology Innovations Read more about BioNTech to Host First Edition of Innovation Series on Diversified Pipeline, Latest Technology Innovations
Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age Read more about Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
Pfizer and BioNTech Provide Update on Rolling Submission to European Medicines Agency for a Potential Variant-Adapted Vaccine Read more about Pfizer and BioNTech Provide Update on Rolling Submission to European Medicines Agency for a Potential Variant-Adapted Vaccine
Information on Dividend Payment and Tax Deduction Read more about Information on Dividend Payment and Tax Deduction
BioNTech to Provide an Update on Manufacturing and Development Plans of mRNA Vaccines in Africa Read more about BioNTech to Provide an Update on Manufacturing and Development Plans of mRNA Vaccines in Africa
Positive Phase 1 Data from mRNA-based Individualized Neoantigen Specific Immunotherapy in Patients with Resected Pancreatic Cancer presented at ASCO Read more about Positive Phase 1 Data from mRNA-based Individualized Neoantigen Specific Immunotherapy in Patients with Resected Pancreatic Cancer presented at ASCO
